Tag: Prurigo nodularis

According to official DUPIXENT prescribing information for patients with chronic obstructive pulmonary disease (COPD), diarrhea was reported in 3.7% of patients receiving a 300 mg dose in clinical trials. While this indicates that DUPIXENT can cause diarrhea, it remains a relatively infrequent side effect compared to others. This guide explores the details of this potential gastrointestinal issue, including its prevalence, possible causes, and effective management strategies.

Vixarelimab is being investigated for conditions involving itch and inflammation. A key aspect is understanding the unique dual mechanism of action of Vixarelimab.

Nemluvio (nemolizumab) is a newer biologic for atopic dermatitis (AD) and prurigo nodularis (PN), entering a market where Dupixent (dupilumab) has been an established treatment for years. To determine if **is Nemluvio better than Dupixent** for a specific patient, it's crucial to evaluate their different mechanisms, administration schedules, and side effect profiles with a healthcare provider.

Clinical trials for Nemluvio show that some patients with atopic dermatitis or prurigo nodularis experience initial itch relief as soon as 48 hours after their first dose. The precise answer to how long does it take Nemluvio to work depends on the condition and individual response, but initial benefits are often seen rapidly.

According to a 2023 study published in *The Lancet*, the investigational human monoclonal antibody **vixarelimab** showed rapid and clinically meaningful reductions in pruritus in patients with moderate-to-severe prurigo nodularis. This promising therapy targets a dual-signaling pathway to address both the intense itch and the skin nodules associated with the condition.